PTPN5

Overview

PTPN5 (also known as STEP, striatal-enriched protein tyrosine phosphatase) encodes a brain-enriched non-receptor tyrosine phosphatase. In the context of cancer pharmacogenomics, PTPN5 expression was identified as a predictive feature for MEK inhibitor sensitivity in the CCLE, likely through its role in modulating ERK/MAPK pathway activity.

Alterations observed in the corpus

• PTPN5 expression was identified as a predictive feature for MEK inhibitor (PD-0325901) sensitivity across 947 cancer cell lines in the CCLE pharmacogenomic profiling study PMID:22460905

Cancer types (linked)

• Pan-cancer cell line panel (947 lines): PTPN5 expression correlates with MEK inhibitor sensitivity PMID:22460905

Co-occurrence and mutual exclusivity

• PTPN5 expression was identified alongside PTEN and SPRY2 expression as additional predictive features for MEK inhibition beyond BRAF/NRAS/KRAS mutation status PMID:22460905

Therapeutic relevance

• PTPN5 expression is a pharmacogenomic predictor of MEK inhibitor (PD-0325901) sensitivity in the CCLE dataset; mechanism likely involves modulation of MAPK pathway flux PMID:22460905

Open questions

• The mechanistic basis for PTPN5 expression correlating with MEK inhibitor sensitivity is not established; it may reflect a feedback phosphatase role in ERK dephosphorylation PMID:22460905

Sources

• PMID:22460905

This page was processed by entity-page-writer on 2026-05-06.